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Objective: To confirm gene transfer techniques especially intothe whole heart, 
we tried out a gene transfer method involving liposome with the viral envelope 
hemagglutinating virus of Japan liposome as an alternative to existing 
techniques such as cationic lipofection or other viral vectors. Method: For this 
study, hemagglutinating virus of Japan liposome (H group) or cationic 
liposome(L group) was used to compare the efficacy of gene transfection of 
oligonucleotide labeled with fluorescein sothiocyanate and cDNA of/]-galac- 
tosidase and human manganese-superoxide dismutase. Fluorescein-labeled 
oligonucleotide, cDNA of /]-galactosidase, or manganese-superoxide dis- 
mutase was complexed with liposomes, DNA-binding nuclear protein, and the 
viral protein coat of hemagglutinating virus of Japan. After donor rat hearts 
arrested by cardioplegia had been harvested, the coronary artery during 
cardioplegic arrest was infused via an aortic annula with the liposome-gene 
complex. Next, the hearts were transplanted into the abdomen of recipient rats 
of the same strain, and all recipients were put to death after 3 days of 
transfection. Results: Fluorescein isothiocyanate was detected in the nuclei of 
more than 70% of the myocytes (75% - 14%, n = 5) in the H group compared 
with fewer than 10% in the L group (7% - 5%, n = 5). The intensity of 
fluorescein isothiocyanate was significantly higher in the H group (979 --+ 112 
FI) than in the L group (116 -+ 68 FI)./3-Galactosidase was expressed in the 
cytosol of more than 50% of the myocytes in the H group (61% --- 7%, n = 5) 
compared with none in the L group (0%, n = 5). After 3 days of gene 
transfection, and when exposed to ischemia (30 minutes, 37 ° C) and reperfu- 
sion (30 minutes, 37 ° C) with Langendorff apparatus, the hearts transfected 
with manganese-superoxide dismutase (S group, n = 5) showed a significantly 
higher percentage ofrecovery of left ventricular end-diastolic pressure (S vs C, 
86% - 3% vs 54% -+ 12%) and coronary flow (98% - 2% vs 66% -+ 12%) than 
did the control hearts (C group, n = 5). Western blotting analysis showed 
an apparent increased expression of manganese-superoxide dismutase in 
the hearts transfected with manganese-superoxide dismutase compared 
with the control hearts. These results clearly demonstrated that the donor 
hearts were transfected with fluorescein-labeled oligonucleotide and the 
/]-galactosidase g ne as a result of coronary infusion of the hemagglutinat- 
ing virus of Japan liposome during cardioplegic arrest at the time of 
harvest. Furthermore, the hearts transfected with manganese-superoxide 
dismutase showed significant improvement in tolerance against ischemia- 
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reperfusion injury. Conclusion: We believe that this method represents a 
novel in vivo gene transfer technique for the heart and thus may provide a 
new tool for research and therapy of heart transplantation. (J Thorac 
Cardiovasc Surg 1997;113:512-9) 
G ene transfer techniques have recently received 
much attention and promise to provide a new 
approach to the prevention and treatment of a number 
of acquired isorders, including those in the cardiovas- 
cular system. 1'a Recently, several groups have demon- 
strated that plasmid DNA is taken up and expressed in
cardiac myocytes after direct injection into the left 
ventricular wall with or without adenovirus vector. 3-6 
However, this technique still presents everal problems 
such as potential evocation of inflammatory esponses, 
resulting in a deleterious effect on myocardial function 
and restriction of the transfected area in the myocar- 
dium, especially to allow for alterations in the genetic 
information of the whole heart. I' 2 Such problems have 
created the need for alternative techniques that incor- 
porate new approaches as well as several kinds of 
vectors. 
As a means of introducing the vectors pecifically 
into the myocardium, coronary infusion seems to be 
more efficient han direct injection for gene transfer 
into the myocardium, provided that the vectors can 
transmigrate through the endothelium. 7' 8 The best 
time for coronary infusion of vectors to perform 
gene transfection to achieve the myocardial protec- 
tion against the ischemic injury or to change allo- 
reactivity after transplantation (or both) appears to 
be during the harvesting of the donor heart. 8' 9 
We have succeeded in establishing an efficient 
gene transfer method by using a liposome with viral 
envelope hemagglutinating virus of Japan (HVJ) 
liposome. 1°43 This method is effective even for 
cardiac myocytes when delivered by coronary infu- 
sion when the donor heart is being harvested. ~3 
The purpose of this study was twofold: (1) to 
compare the efficiency of the HVJ  liposome method 
and the lipofection method for gene transfer into 
the myocardium to confirm the gene transfer tech- 
niques into the whole heart with the HVJ  liposome 
method and (2) to evaluate the efficacy of overex- 
pression of human manganese-superoxide is- 
mutase (Mn-SOD) for alteration of genetic infor- 
mation by the transferred gene with this method. 
Methods 
Animals. Adult Sprague-Dawley rats weighing 250 to 
300 gm were used for this experiment. All rats were 
anesthetized by intraperitoneal injection of sodium pen- 
tobarbital (5 mg/100 gm body weight). 
Oligonucleotide labeled with fluorescein isothiocya- 
nate. In the first experiment, phosphorothioate oligonu- 
cleotide labeled with fluorescein isothiocyanate (FITC- 
ODN; 16-met) was introduced into the myocardium with 
the HVJ liposome method to demonstrate histochemically 
the localization of the transferred genes. FITC-ODN was 
kindly provided by Clontech Inc. (Palo Alto, Calif.). 13-14 
ODN was labeled with FITC on the 3' and 5' ends of the 
ODN by using fluorescein-oligonucleotide phosphoramidite. 
Construction of plasmid. In the second experiment, the 
same method was used to introduce cDNA plasmid of 
/3-galactosidase to demonstrate histochemically the ex- 
pression of transferred genes. 13-Galactosidase was pre- 
pared as described previously. 9 The Escherichia coli 13-ga- 
lactosidase gene (3.1 kb), isolated from pMC1871 by 
restriction with Sal I, was cloned into pAct-c-myb (a gift 
from Dr. Ishii, Institute of Physical and Chemical Re- 
search). 
In the third experiment, we introduced cDNA plasmid 
of human Mn-SOD with the same method to demonstrate 
the efficacy of the transferred genes for alteration of 
cardiac function. A full length of human Mn-SOD cDNA 
was kindly given by Dr. K. Hirose 14 and used to construct 
the Mn-SOD expression vectors designated as pcDNA3- 
Mn-SOD. 
Preparation of HVJ liposome. Liposomes containing 
plasmid DNA and high mobility group 1, which contrib- 
utes to the enhancement of gene mobility in the cyto- 
plasm to the nuclei, were constituted as previously 
reported. 1°-13 In brief, dried lipid (phosphatidylserine, 
phosphatidylcholine, and cholesterol) was mixed with 
plasmid DNA (200 /~g) (previously incubated at 20 ° C 
for 1 hour with high mobility group 1) in each group, 
shaken vigorously, and sonicated to form the liposome. 
Purified HVJ (Z strain) was reactivated by ultraviolet 
irradiation just before use. The liposome suspension 
mixed with HVJ was incubated and, after removal of 
free HVJ, collected for use. 
Preparation of cationic liposome. For the L group, 
cationic liposome, FITC-ODN (30 ng) in the first exper- 
iment or cDNA of/3-galactosidase (200 /zg), was gently 
mixed with 250 /~g of the cationic lipid (Lipofectamine 
[DOSPA: DOPE = 3:1], BRL Life Technologies, Gaith- 
ersburg, Md.) in 500 tzl of sterile saline solution and 
allowed to form a DNA-cationic lipid complex, t5 
In vivo gene transfection. The rat hearts were trans- 
fected as previously reported. In brief, 500 ~1 of HVJ 
liposome complex or cationic liposome complex was de- 
livered into the coronary arteries of the rat hearts through 
the aortic cannula during cardioplegic arrest (<15 °C). 
Then the transfected hearts were heterotopically trans- 
planted according to the method of Ono and Lindsey. 16 
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Fig. 1. Localization of FITC-ODN transfection. The H 
group (A) resulted in an efficient and diffuse transfer of 
FITC-ODN into nuclei of the myocytes in the myocardium. 
Transfer was less efficient and diffuse in group L (B). 
Mean time of cold ischemia (<15 °C) was 25 _+ 12 
minutes. 
Analysis of FITC-ODN. For the analysis of FITC- 
ODN, the hearts were isolated, fixed with 3 % paraformal- 
dehyde, frozen at -80 ° C, cut into thin sections, examined 
with fluorescence microscopy, and micrographed. The 
same sections were stained with hematoxylin and eosin 
and photographed with light microscopy. The percentage 
of FITC-stained nuclei of 200 myocytes was semiquanti- 
tatively calculated by comparing the fluorescence and 
normal micrographs derived from the same area on 10 
randomized sections (magnification, ×100). 
So that the FITC-ODN transferred into the nuclei of 
myocytes could be quantified , the hearts were homoge- 
nized with a digital homogenizer (Iuchi Co., Tokyo, 
Japan) for 3 minutes to break the sarcolemma nd the 
nuclear envelope of the myocytes and centrifuged 
(×1500g) for 10 minutes. The level of FITC at 520 nm of 
the supernatant was then measured with a fluorescence 
spectrophotometer (RF-!500 , Shimadzu Co., Kyoto, Ja- 
pan) and the intensity was described as fluorescence 
intensity per gram wet weight of rat ventricle. 
Analysis of 13-galaetosidase. The hearts were fixed with 
2.5% glutaraldehyde, frozen at -80 ° C, and cut into thin 
sections tained with 5-bromo-4-chloro-3-indolyl /3-D-ga- 
lacto-pyranoside (X-Gal) for identification of the expres- 
sion of 13-galactosidase in the myocardium. 13Then these 
sections were counterstained by hematoxylin and eosin 
staining. To semiquantify the efficacy of protein synthesis 
caused by the transferred genes, we evaluated more than 
200 myocytes at 10 randomized areas (magnification 
× 100) to calculate the percentage of myocytes expressing 
/3-galactosidase. 
Western blotting analysis of Mn-SOD. Western blotting 
analysis for detection of overexpressed Mn-SOD was per- 
formed in the usual fashion. In brief, total protein was 
extracted from homogenized myocardial tissue and electro- 
phoretically separated on a polyacrylamide g l. Mn-SOD 
was detected with monoclonal mouse antibody antihuman 
Mn-SOD (The Binding Site, Birmingham, England) diluted 
at 1:10 in a blotting solution. Specific binding was detected 
with an ECL Western blotting detection set (Amersham Int. 
plc., Buckinghamshire, United Kingdom). 
Evaluation of cardiac function. So that the efficacy of 
the myocardial protective ffect of Mn-SOD gene trans- 
fection could be determined in terms of the recovery of 
cardiac performance, the donor hearts transfected with 
human Mn-SOD cDNA (S group, n = 5) or empty 
liposomes (control group, n = 5) were isolated from the 
recipient abdomen after 3 days of gene transfection. They 
were then cannulated through the aorta, perfused retro- 
gradely with the modified Krebs-Henseleit solution using 
the Langendorff perfusion system, and exposed to isch- 
emia (30 minutes, 37 ° C) and reperfusion (30 minutes, 
37 ° C). After a left ventricular compliant balloon had been 
inserted through the left atrium, left ventricular devel- 
oped pressure (at a left ventricular end-diastolic pressure 
of 10 mm Hg) and coronary effluent flow were measured 
before and 30 minutes after ischemia. Percentage recov- 
eries of control value of left ventricular end-diastolic 
pressure and coronary effluent flow were compared be- 
tween the groups. 
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Fig. 2. Efficiency of FITC-ODN transfection. A, Percentage ofFITC-stained nuclei of myocytes in the H 
group (75% _+ 14%) was significantly higher than that in the L group (7% ± 5%). B, The H group (979 _+ 
1128 FI/gm) showed significantly higher intensity of FITC (FI/gm ventricular wet weight) than did the L 
group (116 ± 68 FI/gm). 
Animal care. All animals received humane care in 
compliance with the "Principles of Laboratory Animal 
Care" formulated by the National Society for Medical 
Research and the "Guide for the Care and Use of 
Laboratory Animals" prepared by the Institute of Lab- 
oratory Animal Resources and published by the Na- 
tional Institutes of Health (NIH Publication No. 86-23, 
revised 1985). We obtained institutional approval of 
our use of animals and biohazardous materials from the 
Institutional Review Board of Osaka University Medi- 
cal School 
Statistics. All values are expressed as mean _+ standard 
deviation. Student's nonpaired t test was used for a 
comparison between two groups, and statistical signifi- 
cance was set at p < 0.05. 
Results 
Localization and efficiency of FITC-ODN trans- 
fection. In the first experiment, aiming to compare 
the efficacy and localization of ODN delivery, we 
introduced FITC-ODN (30 ng/ml) into rat myocar- 
dium by coronary infusion with HVJ liposome 
(group H, n = 5) or with cationic liposome (group L, 
n = 5). The H group (Fig. 1, A) showed a more 
efficient and diffuse transfer of FITC-ODN into the 
nuclei of the myocytes in the myocardium than that 
in group L (Fig. 1, B). 
The percentages of FITC-stained nuclei in myo- 
cytes were 75% _+ 14% in the H group and 7% _+ 
5% in the L group (Fig. 2,A). The percentage in the 
H group was thus significantly higher. 
The intensity of FITC (FI per gram ventricular 
wet weight) was 979 + 112 FI/gm in the H group and 
116 +_ 68 FI/gm in the L group (Fig. 2, B). The H 
group showed significantly higher intensity of FITC 
than did the L group. 
Efficiency of protein synthesi s. In the second 
experiment ~, cDNA of /3-galactosidase with HVJ 
liposome (H group, n = 5) or cationic liposome (L 
group, n = 5) was introduced into rat hearts to 
determine the expression of the transferred gene. 
All hearts in the H group showed apparent histo- 
chemical expression of/3-galactosidase in more than 
50% (61.% _+ 7%) of the myocytes (Fig. 3, A). 
However, no such expression of/3-galactosidase was 
seen in group L (Fig. 3, B). 
The efficacy of Mn-SOD. So that the efficacy of 
Mn-SOD gene transfection could be estimated, the 
hearts in the S group and the C group were sacri- 
ficed and prepared for Western blotting at day 3 of 
transfection. Western blotting analysis showed an 
apparent increase in the expression of Mn-SOD at 
25 kd in the Mn-SOD transfected hearts compared 
with the control hearts (Fig. 4). 
So that  the efficacy of the myocardial protective 
effect of Mn-SOD gene transfection could be deter- 
mined, the recovery of left ventricular end-diastolic 
pressure and coronary flow was measured. The 
percentage of recoveries of control values of left 
ventricular end-diastolic pressure (S vs C, 86% _+ 
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Fig. 3. Efficiency of transfection of ~-galactosidase The hearts in the H group (A, original magnification 
×80) showed apparent histochemical expression of/3-galactosidase n the myocytes. However, no such 
expression of/3-galactosidase was seen in group L (B, original magnification ×80). 
25kDa 
C S 
Fig. 4. Western blotting analysis of Mn-SOD. Western 
blotting analysis showed anapparent increased expression 
of Mn-SOD at 25 kd in the Mn-SOD transfected hearts as 
compared with the control hearts. 
4% vs 51% _+ 7%) and coronary flow (S vs C, 98% 
_+ 2% vs 64% _+ 12%) were significantly higher in 
the Mn-SOD transfected group than in the control 
group (Table I, Fig. 5). 
Discussion 
The results of this study clearly demonstrated that 
the hearts were transfected more effectively with 
both FITC-ODN and cDNA of/3-galactosidase than 
with the cationic liposome as a result of the gene 
transfer using the HVJ liposome. Moreover, the 
hearts transfected with Mn-SOD showed significant 
improvement of tolerance to ischemia-reperfusion 
injury. These findings confirm the gene transfer 
technique into myocardium as a result of coronary 
infusion of the HVJ liposome during cardioplegic 
arrest. 
In the first experiment, he result of FITC-ODN 
indicates the localization of the transferred gene. A 
comparison of FITC intensity between the groups 
transfected with HVJ liposome and cationic lipo- 
some showed that the efficiency of HVJ liposome 
was about 10 times higher than that of cationic 
liposome. This result showed that HVJ liposome 
enhances the gene transfer into the nuclei of myo- 
cytes through the coronary artery when HVJ lipo- 
some is used as a vector. Moreover, the results of 
FITC-ODN may hold promise for the use of this 
method in antisense therapy, an attractive and inno- 
vative strategy of gene therapy. 17' 18 
In the second experiment, more than 50% of 
myocytes in the HVJ liposome group showed ex- 
pression of/9-galactosidase as compared with none 
in the cationic liposome group. This result proved 
the efficiency of protein synthesis after the transfer 
of the gene into the nuclei with this method. It also 
suggests that the HVJ liposome method holds a 
great deal of promise for altering the genetic nfor- 
mation in the myocardium. 
Although it has been reported that Mn-SOD 
plays a significant role as an endogenous myocardial 
protective factor in myocytes, 19'2° there has been 
little direct evidence for the efficacy of overexpres- 
sion of Mn-SOD. Exogenous administration has 
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Fig. 5. The efficacy of the gene transfection ofMn-SOD. The percentage r coveries of control value of left 
ventricular end-diastolic pressure (LVDP; S vs C, 86% ± 3% vs 54% ± 12%) and coronary flow (98% _+ 
2% vs 66% ± 12% ) were significantly higher in the Mn-SOD transfected group (S) than in the control 
group (C). 
Table I 
LVDP (rnm Hg) 
No. Pre Post Recovery (%) Pre 
Coronary flow (ml/min) 
Post Recovery (%) 
S-1 80 73 91 14.1 14 99 
S-2 70 60 85 16.5 16.2 98 
S-3 99 79 80 12.6 12.6 100 
S-4 66 55 83 12 11.4 95 
S-5 76 67 89 13.5 13.5 100 
Mean + SD 86 ± 4* 98 ± 2* 
C-1 104 58 56 11.1 6 54 
C-2 73 31 42 18 13 72 
C-3 93 48 52 20.1 9.6 48 
C-4 67 29 43 14 10 71 
C-5 61 35 58 11 8 73 
Mean ± SD 51 ± 7 64 ± 12 
LVDP, Left ventricular developed pressure; Pre, preischemic control; Post, 30 minutes after reperfusion. 
*p < 0.05 compared with the control group. 
limitations in providing such evidence because of 
the large size of Mn-SOD and the fact that no 
method exists for introducing these large proteins 
specifically into mitochondria in the myocytes. How- 
ever, somatic gene transfer appears to be a potential 
means to overcome these problems. 9 In the third 
experiment, he results demonstrated that rat heart 
can be sufficiently transfected with Mn-SOD gene by 
means of this transfection method followed by an 
improvement in myocardial tolerance to reperfusion 
injury. This suggests that Mn-SOD acts as an endog- 
enous protective factor in the myocardium. Some 
mechanisms of this effect have been speculated on in 
previous reports. One of these is consistent with the 
scavenging of free radicals leaking from mitochon- 
dria.14, ~9, 2o Further investigation is needed for clin- 
ical use of Mn-SOD gene transfection as candidates 
for the treatment of myocardial ischemia-reperfu- 
sion injury. 
For diffuse delivery of genes into the myocardium, 
the infusion of genes through the coronary artery 7' s 
seems to be superior to direct injection into the 
myocardium. A recent report indicated the possibil- 
ity of the infusion of cDNA into the myocardium by 
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using a coronary catheter with an inflated bal loon 
while the heart is beating. 7'8'21 However, this 
method still limits the transfected area in the myo- 
cardium when the whole heart needs to be trans- 
fected. This suggests that a specific period of adhe- 
sion of vector to endothelial cells is needed for 
improvement of this technique. These technical 
considerations may confirm our results that the 
coronary infusion of HVJ  l iposome during car- 
dioplegic arrest promises a unique chance to per- 
form in vivo gene transfection i to the myocardium. 
An  opportune time to perform in vivo gene 
transfection to deliver the vectors may be during 
harvesting of the donor heart, s' 13 Although we used 
a transplantation model that provided good effi- 
ciency of gene transfection, our method can be 
applied to the cardioplegically arrested heart during 
cardiac operations. 13Therefore, these surgical pro- 
cedures might be beneficial for the clinical applica- 
tion of gene therapy and also offer a unique model 
for the study of gene therapy. 
In summary, the donor hearts were transfected 
with F ITC-OND and /3-galactosidase gene as a 
result  of coronary infusion of HVJ  l iposome during 
cardioplegic arrest at the time of harvest. The results 
were compared with the results of transfection with 
cationic liposome. Hearts transfected with Mn-SOD 
showed significant improvement of tolerance to 
ischemia-reperfusion injury. Our method appears to 
be a novel in vivo gene transfer technique for the 
heart to be subjected to ischemia, and thus may 
provide a new tool for research and therapy of heart 
transplantation. 
We thank Dr. K. Hirose for kindly giving us a full-length 
of human Mn-SOD cDNA. 
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Discussion 
Dr. Edward D. Verrier (Seattle, Wash.). At the Univer- 
sity of Washington, one of our faculty, Margaret Allen, 
has used a similar method to transfect a number of cells, 
but she uses just plain liposomes without the viral enve- 
lope. And in contrast, she gets about an 80% transference 
of the /3-galactosidase reporter gene. How do you think 
that that makes it more efficient in terms of the transfer? 
What is the mechanism? 
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Dr. Sawa. For in vivo gene transfection i to the entire 
heart, it seems very difficult to transfer gene by plasmid 
DNA or liposome alone. HVJ has a membrane fusion 
function. On its lipid bilayer surface, it has two proteins, 
HN protein and F protein. HN protein can promote 
adhesion or binding between liposome and endothelial 
cells, and F protein acts for fusion after adhesion. There- 
fore, with HVJ, liposome containing cDNA can easily 
bind to cells and then such DNA in the liposome can 
easily go through the cytoplasm and enter directly into the 
nucleus. The HVJ liposome method appears to work 
efficiently to promote gene therapy for the heart. 
Dr. James K. Kirldin (Birmingham, Ala.). Dr. Sawa, it is 
my understanding that the duration of expression of these 
genes is relatively short. Although this method would be 
potentially useful in ischemic reperfusion models, what 
about its applicability to the prevention of rejection after 
transplantation when a longer expression of the gene 
would be necessary? 
Dr. Sawa. With the HVJ liposome method the efficient 
period of gene transfection is limited. However, an advan- 
tage of HVJ is that it can be administered more than two 
times without any cytotoxicity and antigenicity, unlike 
adenovirus or other viral vectors. Therefore this method 
can be applied to prevent rejection for a long time by 
means of intermittent and repeated administration of 
HVJ liposome. 
Dr. Frank W. Sellke (Boston, Mass.). Did you look at 
the protein expression for the SOD? There is already a lot 
of SOD in the vascular tissue and the myocardium, and a 
small incremental increase may not have a great effect. 
You clearly showed improvement in function and coro- 
nary flow, but did you actually look at the expression of 
SOD? 
Dr. Sawa. In view of the Western blotting analysis, we 
have already detected the expression of Mn-SOD at 25 kd 
in the gene transfected heart. Almost all myocytes showed 
its apparent expression immunohistochemically. 
